Lipanthyl

Fenofibrate, the active ingredient in Lipanthyl, is a fibrate presented as an oral tablet for oral use. It is prescribed to manage elevated lipid levels, particularly high triglycerides and cholesterol, in adults with dyslipidaemia. GNH USA supplies Lipanthyl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipanthyl (fenofibrate) acts on lipid metabolism disorders and is used for the following clinical conditions: - Hypercholesterolemia: lowers total and LDL cholesterol levels. - Hypertriglyceridemia: reduces serum triglyceride concentrations. - Mixed dyslipidemia: improves the overall lipid profile by decreasing triglycerides and LDL while modestly raising HDL cholesterol.

Adverse reactions to fenofibrate may vary in frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia. - Elevated liver enzymes: mild transaminase increases. - Muscle pain: myalgia without severe weakness. - Headache: mild to moderate intensity. - Skin reactions: rash or pruritus.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with dark urine. - Hepatotoxicity: significant elevation of liver enzymes or jaundice. - Renal impairment: worsening kidney function. - Severe hypersensitivity: angioedema or anaphylactoid reactions. - Gallstones: increased risk of biliary sludge formation.

Before initiating therapy, consider the following safety measures: - Liver function: assess baseline hepatic enzymes and monitor periodically. - Renal function: evaluate creatinine clearance, especially in patients with existing kidney disease. - Muscle health: avoid concomitant use with statins without monitoring for myopathy. - Pregnancy and lactation: use only if the potential benefit outweighs risk, as safety data are limited. - Drug interactions: review all concomitant medications for possible interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Fenofibrate may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Statins (high‑dose): increased risk of rhabdomyolysis. - Anticoagulants (warfarin): potentiation of anticoagulant effect. - Bile‑acid sequestrants: reduced fenofibrate absorption.

Moderate Interactions (Monitor Closely): - Immunosuppressants (cyclosporine, tacrolimus): possible increase in serum levels. - Oral hypoglycemics: enhanced glucose‑lowering effect. - Thyroid hormones: potential alteration of thyroid function tests.